PMID- 29633178
OWN - NLM
STAT- MEDLINE
DCOM- 20190613
LR  - 20190613
IS  - 0171-2004 (Print)
IS  - 0171-2004 (Linking)
VI  - 252
DP  - 2018
TI  - Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances.
PG  - 143-164
LID - 10.1007/164_2018_113 [doi]
AB  - New psychoactive substances (NPS) with amphetamine-, aminoindan-, and benzofuran 
      basic chemical structures have recently emerged for recreational drug use. 
      Detailed information about their psychotropic effects and health risks is often 
      limited. At the same time, it emerged that the pharmacological profiles of these 
      NPS resemble those of amphetamine or 3,4-methylenedioxymethamphetamine (MDMA). 
      Amphetamine-like NPS induce psychostimulation and euphoria mediated predominantly 
      by norepinephrine (NE) and dopamine (DA) transporter (NET and DAT) inhibition and 
      transporter-mediated release of NE and DA, thus showing a more 
      catecholamine-selective profile. MDMA-like NPS frequently induce well-being, 
      empathy, and prosocial effects and have only moderate psychostimulant properties. 
      These MDMA-like substances primarily act by inhibiting the serotonin (5-HT) 
      transporter (SERT) and NET, also inducing 5-HT and NE release. Monoamine receptor 
      interactions vary considerably among amphetamine- and MDMA-like NPS. Clinically, 
      amphetamine- and MDMA-like NPS can induce sympathomimetic toxicity. The aim of 
      this chapter is to review the state of knowledge regarding these substances with 
      a focus on the description of the in vitro pharmacology of selected amphetamine- 
      and MDMA-like NPS. In addition, it is aimed to provide links between 
      pharmacological profiles and in vivo effects and toxicity, which leads to the 
      conclusion that abuse liability for amphetamine-like NPS may be higher than for 
      MDMA-like NPS, but that the risk for developing the life-threatening serotonin 
      syndrome may be increased for MDMA-like NPS.
FAU - Simmler, Linda D
AU  - Simmler LD
AD  - Department of Basic Neurosciences, University of Geneva, Geneva, Switzerland. 
      linda.simmler@unige.ch.
FAU - Liechti, Matthias E
AU  - Liechti ME
AD  - Division of Clinical Pharmacology and Toxicology, University Hospital Basel, 
      Basel, Switzerland. matthias.liechti@usb.ch.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Germany
TA  - Handb Exp Pharmacol
JT  - Handbook of experimental pharmacology
JID - 7902231
RN  - 0 (Central Nervous System Stimulants)
RN  - 0 (Dopamine Plasma Membrane Transport Proteins)
RN  - 0 (Norepinephrine Plasma Membrane Transport Proteins)
RN  - 0 (Psychotropic Drugs)
RN  - 0 (Serotonin Antagonists)
RN  - CK833KGX7E (Amphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Amphetamine
MH  - Central Nervous System Stimulants/*pharmacology
MH  - Dopamine Plasma Membrane Transport Proteins/antagonists & inhibitors
MH  - Humans
MH  - N-Methyl-3,4-methylenedioxyamphetamine
MH  - Norepinephrine Plasma Membrane Transport Proteins/antagonists & inhibitors
MH  - Psychotropic Drugs/*pharmacology
MH  - Serotonin Antagonists
OTO - NOTNLM
OT  - 4-FA
OT  - 4-Fluoroamphetamine
OT  - 5-IT
OT  - Aminoindans
OT  - Amphetamine
OT  - Benzofurans
OT  - DAT
OT  - Dopamine
OT  - MDMA
OT  - Monoamines
OT  - NET
OT  - NPS
OT  - Noradrenaline
OT  - Release
OT  - SERT
OT  - Serotonin
OT  - Uptake
EDAT- 2018/04/11 06:00
MHDA- 2019/06/14 06:00
CRDT- 2018/04/11 06:00
PHST- 2018/04/11 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2018/04/11 06:00 [entrez]
AID - 10.1007/164_2018_113 [doi]
PST - ppublish
SO  - Handb Exp Pharmacol. 2018;252:143-164. doi: 10.1007/164_2018_113.